Hereby, we aimed to predict response to treatment in HER2‐negative, early‐stage breast cancer patients treated in the Dutch Breast Cancer Research Group (BOOG) phase III, randomized, multicenter DIRECT23 and NEOZOTAC trials.24 The gene discussed is ERBB2; the disease is breast cancer.